Related Experiment Video
Updated: Aug 1, 2025
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
Hirokazu Naganawa1, Akira Ito1, Shinrou Saiki1
1Department of Cardiology, Toyokawa City Hospital, Toyokawa, Aichi, Japan.
Insights
Drug-coated balloons (DCBs) show comparable efficacy to drug-eluting stents (DES) for acute coronary syndrome (ACS) patients. DCB therapy is a valuable alternative, demonstrating similar major adverse cardiovascular events rates in this study.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomaterials Science
Background:
- Drug-eluting stents (DES) are standard for acute coronary syndrome (ACS) but carry risks like bleeding and restenosis.
- Drug-coated balloons (DCBs) offer a potential solution to mitigate stent-associated complications.
- Neoatherosclerosis and stent thrombosis are persistent challenges with DES therapy.
Purpose of the Study:
- To evaluate the efficacy of drug-coated balloon (DCB) therapy.
- To compare DCB therapy with drug-eluting stent (DES) therapy in ACS patients.
- To assess the one-year incidence of major adverse cardiovascular events (MACE) in both treatment groups.
Main Methods:
- Single-center, retrospective, observational study.
- Included ACS patients treated with either DCB or DES from July 2014 to November 2020.
- Excluded patients with left main trunk lesions; primary outcome was MACE at one year.
Main Results:
- 83 patients received DCB, and 372 patients received DES.
- The incidence of MACE was 12.0% in the DCB group and 13.4% in the DES group.
- No significant difference in MACE was observed between the DCB and DES groups (P=0.73).
Conclusions:
- Drug-coated balloons (DCBs) are effective and valuable for treating patients with acute coronary syndrome (ACS).
- DCB therapy presents a viable alternative to drug-eluting stents (DES) for ACS management.
- Further research may solidify DCB's role in reducing long-term complications.
Background:
Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS.
Materials And Methods:
In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year.
Results:
Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73).
Conclusions:
DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction